Category Archives: Indian Patent Office

MSF approaches Delhi High Court to challenge unmerited patent grant for pneumonia vaccine

New Delhi, 13 October 2017 – Médecins Sans Frontières/Doctors Without Borders India has filed a petition before the High Court of Delhi to overturn the patent granted on the pneumococcal conjugate vaccine (PCV) to the US pharmaceutical corporation Pfizer. Earlier … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Patent, Patent examination system, Patent Opposition, Uncategorized | Tagged , , | Leave a comment

Pfizer patent for pneumonia drug could have a deadly impact on public health

India carries the world’s highest burden of pneumonia and accounts for nearly 20% of global infant pneumonia deaths Opinion piece: Leena Menghaney, The Hindustan Times India’s Patent Office has dealt a major setback to hopes for improved access to an … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Dangerous pneumonia on the loose, but affordable vaccine to get tough to procure; uproar sparked off; reason will SHOCK you

Source: The Financial Express Access to affordable pneumococcal conjugate vaccine (PCV) will become tougher after the Indian patent office granted a patent to US pharma major Pfizer for its PCV13 product, marketed as Prevnar13. Access to affordable pneumococcal conjugate vaccine … Continue reading

Posted in Indian Patent Office, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Amid opposition, India gives Pfizer the patent to exclusively sell vital pneumonia vaccine

Various groups believe the decision will make the shot less accessible to the poor. Source: Scroll India has granted Mumbai-based pharmaceutical company Pfizer Inc a patent for its pneumonia vaccine Prevenar 13, amid opposition from groups that say the decision … Continue reading

Posted in Indian Patent Office, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Indian patent office delivers major blow to affordable pneumonia vaccine hopes

MSF Access Campaign August 22, 2017   Geneva/New York/New Delhi, 22 August 2017 – Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that safeguards both children and adults from pneumonia was dealt a major blow after the Indian … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Patent, Patent Opposition, Patent Term Extension, Uncategorized, Vaccines | Tagged , | Leave a comment

Drugs row threatens health sector budget

Source: Daily Nation; October 6, 2015 Kenya may be forced to increase its future annual health budget, if global drug companies have their way in the simmering patents row surrounding the manufacture of medicines. They have pushed India, Kenya’s biggest … Continue reading

Posted in EU-India FTA, Indian Patent Law, Indian Patent Office, IP Rights, IPR policy, LDCs, Uncategorized | Leave a comment

Maths of Gilead’s hepatitis C drug

Source: Down To Earth 3 Feb 2015 Why US firm’s super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price The indian Patent Office’s rejection of one of Gilead Sciences’ patents … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patent Opposition, Patents, Pricing, Sofosbuvir | Leave a comment